
Pfizer to begin auction of consumer health division next month
pharmafile | October 26, 2017 | News story | Sales and Marketing | GSK, Pfizer, Proctor & Gamble, Sanofi, nestle
Following the recent revelation that Pfizer was considering the spin-out of its consumer health division, it has now emerged that the pharma giant is planning to launch an auction process to secure its sale and the $15 billion-plus it is looking for for the unit.
Pfizer announced it was weighing up its strategic options for the business unit on 10 October, and CEO Emma Walmsley this week said she would be “carefully” assessing these options. To this end, the drug maker has been reported to have already engaged in discussions with prospective buyer Reckitt Benckiser.
The unit deals with well-known brands such as painkiller Advil and lip balm Chapstick generated $3.4 billion in sales last year, attracting a list of other interested buyers including GlaxoSmithKline, Johnson & Johnson, Sanofi, Proctor & Gamble and Nestle.
According to reports, Pfizer plans to push through progress in the area by the end of the year, and will send out financial information to interested parties in the next three weeks. It is expected that the unit could be sold by the middle of next year.
Matt Fellows
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …





